Patents by Inventor Alaa Knany

Alaa Knany has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GUANINE-RICH DEOXYRIBOZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240344064
    Abstract: Provided herein are modified DNAzymes, including DNAzymes with overhang sequences not complementary to the target RNA, in particular, overhangs with high G content. Also provided are compositions comprising the DNAzyme; vectors including the DNAzymes; pharmaceutical compositions including the vectors; and methods including any of the above for cleaving a target RNA; inducing cell death; and treating various diseases and disorders.
    Type: Application
    Filed: August 4, 2022
    Publication date: October 17, 2024
    Applicant: 1E Therapeutics, Ltd.
    Inventors: Ido BACHELET, Almogit ABU-HOROWITZ, Gat KRIEGER, Yossi OVADYA, Dina RAICHLIN, Etti KATZ-KADOSH, Alaa KNANY, Shireen BARAKEY, Noam BOROVSKY, Noam COHEN, Hagai MARMOR-KOLLET, Alexander ROSENBERG, Adva LEVY-ZAMIR
  • p21 mRNA target areas for silencing
    Patent number: 11981896
    Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: May 14, 2024
    Assignee: 1E Therapeutics Ltd.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGETING DNAZYMES
    Publication number: 20240076671
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 7, 2024
    Applicant: Rehovot
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 mRNA targeting DNAzymes
    Patent number: 11879140
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: January 23, 2024
    Assignee: 1E THERAPEUTICS LTD.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGETING DNAZYMES
    Publication number: 20230365952
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42. 45-48. 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 16, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGET AREAS FOR SILENCING
    Publication number: 20230357771
    Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 9, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet